company background image
MOR

MorphoSys XTRA:MOR Stock Report

Last Price

€23.81

Market Cap

€816.9m

7D

2.5%

1Y

13.5%

Updated

29 May, 2023

Data

Company Financials +

MOR Stock Overview

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States.

MOR fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

MorphoSys AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MorphoSys
Historical stock prices
Current Share Price€23.81
52 Week High€24.92
52 Week Low€11.81
Beta0.76
1 Month Change24.92%
3 Month Change38.63%
1 Year Change13.49%
3 Year Change-79.59%
5 Year Change-73.99%
Change since IPO252.74%

Recent News & Updates

Does MorphoSys (ETR:MOR) Have A Healthy Balance Sheet?

May 16
Does MorphoSys (ETR:MOR) Have A Healthy Balance Sheet?

Recent updates

Does MorphoSys (ETR:MOR) Have A Healthy Balance Sheet?

May 16
Does MorphoSys (ETR:MOR) Have A Healthy Balance Sheet?

MorphoSys AG (ETR:MOR) Held Back By Insufficient Growth Even After Shares Climb 36%

Apr 17
MorphoSys AG (ETR:MOR) Held Back By Insufficient Growth Even After Shares Climb 36%

MorphoSys AG (ETR:MOR) Analysts Are More Bearish Than They Used To Be

Nov 26
MorphoSys AG (ETR:MOR) Analysts Are More Bearish Than They Used To Be

News Flash: 10 Analysts Think MorphoSys AG (ETR:MOR) Earnings Are Under Threat

Mar 21
News Flash: 10 Analysts Think MorphoSys AG (ETR:MOR) Earnings Are Under Threat

MorphoSys AG (ETR:MOR) Analysts Just Slashed Next Year's Revenue Estimates By 10%

Jan 12
MorphoSys AG (ETR:MOR) Analysts Just Slashed Next Year's Revenue Estimates By 10%

Health Check: How Prudently Does MorphoSys (ETR:MOR) Use Debt?

Dec 04
Health Check: How Prudently Does MorphoSys (ETR:MOR) Use Debt?

Is MorphoSys (ETR:MOR) A Risky Investment?

Aug 19
Is MorphoSys (ETR:MOR) A Risky Investment?

These Analysts Just Made A Huge Downgrade To Their MorphoSys AG (ETR:MOR) EPS Forecasts

Mar 17
These Analysts Just Made A Huge Downgrade To Their MorphoSys AG (ETR:MOR) EPS Forecasts

Will Weakness in MorphoSys AG's (ETR:MOR) Stock Prove Temporary Given Strong Fundamentals?

Feb 22
Will Weakness in MorphoSys AG's (ETR:MOR) Stock Prove Temporary Given Strong Fundamentals?

What Kind Of Shareholders Hold The Majority In MorphoSys AG's (ETR:MOR) Shares?

Jan 17
What Kind Of Shareholders Hold The Majority In MorphoSys AG's (ETR:MOR) Shares?

The MorphoSys (ETR:MOR) Share Price Has Gained 62% And Shareholders Are Hoping For More

Dec 14
The MorphoSys (ETR:MOR) Share Price Has Gained 62% And Shareholders Are Hoping For More

Shareholder Returns

MORDE BiotechsDE Market
7D2.5%-0.04%-1.3%
1Y13.5%-4.7%-8.5%

Return vs Industry: MOR exceeded the German Biotechs industry which returned -6.1% over the past year.

Return vs Market: MOR exceeded the German Market which returned -8.1% over the past year.

Price Volatility

Is MOR's price volatile compared to industry and market?
MOR volatility
MOR Average Weekly Movement7.3%
Biotechs Industry Average Movement6.0%
Market Average Movement5.0%
10% most volatile stocks in DE Market9.9%
10% least volatile stocks in DE Market2.7%

Stable Share Price: MOR is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: MOR's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1992623Jean-Paul Kresshttps://www.morphosys.com

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1.

MorphoSys AG Fundamentals Summary

How do MorphoSys's earnings and revenue compare to its market cap?
MOR fundamental statistics
Market Cap€816.91m
Earnings (TTM)-€72.84m
Revenue (TTM)€299.12m

2.7x

P/S Ratio

-11.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MOR income statement (TTM)
Revenue€299.12m
Cost of Revenue€61.71m
Gross Profit€237.41m
Other Expenses€310.25m
Earnings-€72.84m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

Aug 09, 2023

Earnings per share (EPS)-2.13
Gross Margin79.37%
Net Profit Margin-24.35%
Debt/Equity Ratio246.7%

How did MOR perform over the long term?

See historical performance and comparison